PMID- 19601856
OWN - NLM
STAT- MEDLINE
DCOM- 20090826
LR  - 20191027
IS  - 1570-1611 (Print)
IS  - 1570-1611 (Linking)
VI  - 7
IP  - 3
DP  - 2009 Jul
TI  - New anticoagulants: focus on venous thromboembolism.
PG  - 309-29
AB  - Anticoagulation is recommended for prophylaxis and treatment of venous 
      thromboembolism (VTE) (deep vein thrombosis and pulmonary embolism) and/or 
      arterial thromboembolism. The therapeutic arsenal of anticoagulants available to 
      clinicians is mainly composed by unfractionated heparin (UFH), 
      low-molecular-weight heparin (LMWH), fondaparinux and oral vitamin K antagonists 
      (VKA) (i.e. warfarin and acenocumarol). These anticoagulants are effective, but 
      they require parenteral administration (UFH, LMWH, fondaparinux) and/or frequent 
      anticoagulant monitoring (intravenous UFH, oral VKA). Novel anticoagulants in 
      clinical testing include orally active direct factor II inhibitors [dabigatran 
      etexilate (BIBR 1048), AZD0837)], parenteral direct factor II inhibitors 
      (flovagatran sodium), orally active direct factor X inhibitors [rivaroxaban (BAY 
      59-7939), apixaban, betrixaban, YM150, DU-176b, LY-517717, GW813893, TAK-442, PD 
      0348292] and new parenteral FXa inhibitors [idraparinux, idrabiotaparinux 
      (biotinilated idraparinux; SSR 126517), ultra-low-molecular-weight heparins 
      (ULMWH: AVE5026, RO-14)]. These new compounds have the potential to complement 
      heparins and fondaparinux for short-term anticoagulation and/or to replace VKA 
      for long-term anticoagulation in most patients. Dabigatran and rivaroxaban have 
      been the firsts of the new oral anticoagulants to be licensed for the prevention 
      of VTE after hip and knee replacement surgery. In the present review, we discuss 
      the pharmacology of new anticoagulants, the key points necessary for interpreting 
      the results of studies on VTE prophylaxis and treatment, the results of clinical 
      trials testing these new compounds and their potential advantages and drawbacks 
      over existing therapies.
FAU - Gomez-Outes, Antonio
AU  - Gomez-Outes A
AD  - Division of Pharmacology and Clinical Drug Evaluation, Spanish Agency for 
      Medicines and Medical Devices (AEMPS), Madrid, Spain. agomezo@agemed.es
FAU - Lecumberri, Ramon
AU  - Lecumberri R
FAU - Pozo, Carmen
AU  - Pozo C
FAU - Rocha, Eduardo
AU  - Rocha E
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
RN  - 0 (Anticoagulants)
RN  - 0 (Drugs, Investigational)
RN  - 0 (Factor Xa Inhibitors)
RN  - EC 3.4.21.5 (Thrombin)
SB  - IM
MH  - Administration, Oral
MH  - Anticoagulants/*administration & dosage/adverse effects/pharmacology
MH  - Clinical Trials as Topic
MH  - Drugs, Investigational/*administration & dosage/adverse effects/pharmacology
MH  - *Factor Xa Inhibitors
MH  - Humans
MH  - Models, Biological
MH  - Thrombin/*antagonists & inhibitors
MH  - Venous Thromboembolism/*drug therapy/prevention & control
RF  - 152
EDAT- 2009/07/16 09:00
MHDA- 2009/08/27 09:00
CRDT- 2009/07/16 09:00
PHST- 2009/07/16 09:00 [entrez]
PHST- 2009/07/16 09:00 [pubmed]
PHST- 2009/08/27 09:00 [medline]
AID - 10.2174/157016109788340785 [doi]
PST - ppublish
SO  - Curr Vasc Pharmacol. 2009 Jul;7(3):309-29. doi: 10.2174/157016109788340785.